目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T60856 | |||
HDAC6-IN-9 (compound 12c) 是 HDAC6的强效选择性抑制剂,具有抗增殖活性。HDAC6-IN-9 对 HDAC6、HDAC1、HDAC3、HDAC8 和 HDAC10 的 IC50值分别为 4.2, 11.8, 15.2, 139.6, 21.3 nM。 | |||
T68796 | |||
Thr101, also known as NOX Inhibitor VII, is a dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9. Thr101 is also a NOX inhibitor. | |||
T63509 | |||
Top/HDAC-IN-1 是拓扑异构酶 (Top)/HDAC 双重抑制剂,能够作用于 HDAC1 (IC50: 18 nM)、HDAC2 (IC50: 230 nM)、HDAC3 (IC50: 790 nM)、HDAC6 (IC50: 87 nM) 和 HDAC8 (IC50: 5250 nM)。Top/HDAC-IN-1 对 HCT116 细胞表现出有效的抗肿瘤作用 (IC50: 180 nM),可将 HCT116 细胞的细胞周期阻滞 G2 期,有效诱导其凋亡 (apoptosis)。 | |||
T61727 | |||
HDAC6/8/BRPF1-IN-1 is a dual inhibitor that targets HDAC6, HDAC8, and the bromodomain and PHD finger containing protein 1 (BRPF1). It exhibits inhibitory activity against HDAC1, HDAC6, and HDAC8 with IC50 values of 797 nM, 344 nM, and 908 nM, respectively. In addition, it inhibits BRPF1 with a Kd value of 175.2 nM. This compound is utilized in cancer research [1]. | |||
T2025 | HDAC | ||
HDAC-IN-7 (HBI-8000) 是 Chidamide 的一种杂质。Chidamide 是一种可口服的 HDAC 酶 I 类 HDAC1/2/3 和 IIb 类 HDAC10 抑制剂。 | |||
T3205 | HDAC | ||
UF010 是一种有效的选择性 HADC 抑制剂,对 HDAC 1、2、3 和 8 的 IC50 分别为 0.5 μM、0.1 μM、0.06 μM 和 1.5 μM。它比作用于其他HDACs 选择性高6倍多。 | |||
T62006 | |||
HDAC-IN-30 是多种HDAC 蛋白的抑制剂,包括HDAC1(IC50=13.4 nM),HDAC2(IC50=28.0 nM),HDAC3(IC50=9.18 nM),HDAC6(IC50=42.7 nM),HDAC8(IC50=131 nM)。HDAC-IN-30 显示除强大的抗肿瘤作用。 | |||
T62708 | |||
HDAC-IN-37 是一种 HDAC 的有效抑制剂,作用于 HDAC1 (IC50: 0.0551 μM)、HDAC3 (IC50: 1.24 μM)、HDAC8 (IC50: 0.948 μM) 和 HDAC6 (IC50: 34.2 μM)。HDAC-IN-37 能够缓慢诱导组蛋白乙酰化。HDAC-IN-37 阻碍细胞由 G1 期向 S 期转变,诱导早期细胞凋亡。 | |||
T62327 | |||
HDAC2-IN-1 (Compound 17) 是一种口服具有活力的、能够透过血脑屏障的、竞争性 HDAC2 抑制剂 (IC50: 0.5 μM)。HDAC2-IN-1 也能够抑制 HDAC1 (IC50: 1.61 μM) 和 HDAC8 (IC50: 0.98 μM)。 | |||
T78880 | |||
Tubulin/HDAC-IN-3(compound 12a)为一种高效的tubulin/HDAC汇合型抑制剂,能显著破坏微管蛋白聚合(IC50: 5.4 μM),并对HDAC1/8展现强效抑制作用,IC50值分别为0.155 μM和0.177 μM。该化合物通过阻断细胞周期、诱导细胞凋亡(apoptosis)及抑制集落形成以施展其生物学效用。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02317 | HDAC8 Protein, Mouse, Recombinant (His) | Mouse | Baculovirus-Insect Cells | ||
Histone deacetylase 8, also known as HDAC8 and HDACL1, is a nucleus and cytoplasm protein that belongs to the histone deacetylase family and HD type 1 subfamily. Histone deacetylases (HDACs) are a growing family of enzymes implicated in transcriptional regulation by affecting the acetylation state of core histones in the nucleus of cells. HDAC8 / HDACL1 is weakly expressed in most tissues. It is expressed at a higher level in the heart, brain, kidney, and pancreas and also in the liver, lung, placenta, prostate, and kidney. HDAC8 / HDACL1 is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones ( H2A, H2B, H3, and H4 ). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. HDAC8 / HDACL1 may play a role in smooth muscle cell contractility. HDAC8 / HDACL1 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.
|
|||||
TMPY-01333 | HDAC8 Protein, Human, Recombinant (GST) | Human | Baculovirus-Insect Cells | ||
Histone deacetylase 8, also known as HDAC8 and HDACL1, is a nucleus and cytoplasm protein that belongs to the histone deacetylase family and HD type 1 subfamily. Histone deacetylases (HDACs) are a growing family of enzymes implicated in transcriptional regulation by affecting the acetylation state of core histones in the nucleus of cells. HDAC8 / HDACL1 is weakly expressed in most tissues. It is expressed at a higher level in the heart, brain, kidney, and pancreas and also in the liver, lung, placenta, prostate, and kidney. HDAC8 / HDACL1 is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones ( H2A, H2B, H3, and H4 ). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. HDAC8 / HDACL1 may play a role in smooth muscle cell contractility. HDAC8 / HDACL1 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.
|